NCT03166644View on ClinicalTrials.gov

Individualized Goal-directed Sufentanil Administration Versus Standard Therapy in Patients Undergoing Major Abdominal Surgery

NACompletedINTERVENTIONAL
Enrollment

128

Participants

Timeline

Start Date

July 4, 2017

Primary Completion Date

January 20, 2019

Study Completion Date

January 20, 2019

Conditions
Major Abdominal Surgery
Interventions
DEVICE

Analgesia Nociception Index (ANI)-guided sufentanil administration

One recent observational study showed that ANI-guided remifentanil administration during vascular surgery resulted in low opioid consumption and low postoperative pain rates.

Trial Locations (1)

63003

CHU de Clermont-Ferrand, Clermont-Ferrand

All Listed Sponsors
collaborator

Rennes University Hospital

OTHER

collaborator

University Hospital, Montpellier

OTHER

lead

University Hospital, Clermont-Ferrand

OTHER

NCT03166644 - Individualized Goal-directed Sufentanil Administration Versus Standard Therapy in Patients Undergoing Major Abdominal Surgery | Biotech Hunter | Biotech Hunter